Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO? (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States
BusinessWire
September 19, 2017
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Nuvelution Pharma, Inc. today announced their partnership to develop AUSTEDO? (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome (TS) in pediatric patients in the United States. This partnership will accelerate development of Austedo? in TS, hopefully bringing a much needed new treatment option to affected young patients more quickly.
About AUSTEDO
AUSTEDO? is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington?s disease.
Complete article
Related articles:
Globes English - Teva teams with Nuvelution on Tourette syndrome drug
BioPharm-Dive
Attached is PDF
of U.S. Full Prescribing Information, including Boxed Warning
BusinessWire
September 19, 2017
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Nuvelution Pharma, Inc. today announced their partnership to develop AUSTEDO? (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome (TS) in pediatric patients in the United States. This partnership will accelerate development of Austedo? in TS, hopefully bringing a much needed new treatment option to affected young patients more quickly.
About AUSTEDO
AUSTEDO? is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington?s disease.
Complete article
Related articles:
Globes English - Teva teams with Nuvelution on Tourette syndrome drug
BioPharm-Dive
Attached is PDF
of U.S. Full Prescribing Information, including Boxed Warning